Trials / Completed
CompletedNCT00426348
A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Guangdong Provincial People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
a statement of the study hypothesis:the effect of valsartan in patients with IgA nephropathy have been proved,and the efficacy of probucol in combination with valsartan is to be proved in patients with IgA nephropathy. This is a prospective randomized controlled, double blinded pilot study to identify the efficacy of probucol in combination with valsartan in patients with IgA nephropathy. The renal function deterioration will be the primary outcome studied. The expected study duration will be 36 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valsartan | Valsartan (80-160mg/day) |
| DRUG | Probucol | Probucol (750mg/day) |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2013-01-01
- Completion
- 2013-01-01
- First posted
- 2007-01-24
- Last updated
- 2013-08-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00426348. Inclusion in this directory is not an endorsement.